Xeris Biopharma gets USPTO notice of allowance for Keveyis patent extending protection to 2039

XERIS PHARMACEUTICALS INC

XERIS PHARMACEUTICALS INC

XERS

0.00
  • Xeris Biopharma received a USPTO Notice of Allowance for a new U.S. patent application covering use of its Keveyis (dichlorphenamide) product.
  • The patent is expected to provide intellectual property protection for Keveyis through 2039, subject to issuance and maintenance fees.
  • Xeris plans to submit the patent to the FDA for listing in the Orange Book once it issues.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606111639BIZWIRE_USPR_____20260611_BW817161) on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.